How Long Does Hair Loss Treatment Take? A Realistic Timeline

How long does hair loss treatment take? For most people, the first visible changes appear around months 4 to 6, and the bulk of the improvement typically shows by month 12. The exact timing is shaped less by the medication and more by the biology of the hair growth cycle: hair grows slowly, follicles take time to shift between phases, and any medication that influences these processes works on the timeline of months, not days. Results vary from person to person.

This page explains what to realistically expect during the first year of treatment for androgenetic alopecia, why patience is part of the protocol, and what each phase actually involves.

Hair loss treatment timeline at a glance

These windows are typical rather than guaranteed. Individual response varies with the stage of hair loss when treatment begins, how consistently the medication is used, and which medications are involved, so progress is best evaluated with a clinician over months rather than judged week to week.

Why hair loss treatment takes time

The hair growth cycle has three phases:

• Anagen: the active growth phase, which normally lasts 2 to 6 years on the scalp
• Catagen: a brief transition phase of approximately 2 weeks
• Telogen: the resting phase, lasting roughly 3 months, after which the hair sheds and a new one begins to grow

At any given time, around 85-90% of scalp hairs are in anagen, 1-2% in catagen, and 10-15% in telogen. Treatments that influence the cycle (by extending anagen or by reducing the hormonal pressure that shortens it) cannot bypass these durations. They operate within the cycle's natural timing, which is why visible results take months to emerge.

Both minoxidil and finasteride affect specific points in this cycle, and the changes they produce accumulate gradually as follicles transition through their phases.

The first month: little visible change

In the first 30 days, most patients see no clear change in their hair. The medications are present in the body and beginning to act on follicle biology, but the existing hair on the scalp has already committed to its current cycle. The visible scalp at month 1 is essentially the scalp at month 0.

Two things may happen in this first month:

• Mild scalp irritation from topical minoxidil, particularly with the alcohol-based solution; this usually subsides as the scalp adjusts
• Awareness of normal shedding, since many people pay closer attention to hair loss after starting treatment than they did before, leading some to misinterpret routine daily shedding as a worsening condition

Patience is appropriate at this stage. Discontinuing treatment because nothing visible has happened by week 4 is one of the most common reasons patients fail to benefit from therapy.

Months 2 to 3: the shedding phase

A significant proportion of patients experience increased shedding during the second or third month of treatment, particularly when starting minoxidil. This is sometimes called the "shedding phase" or "stress shed". It is a recognised early effect of starting treatment rather than an indication that the treatment is failing.

Why shedding occurs

Minoxidil pushes follicles in the resting phase out of telogen and into a new anagen phase. This means hairs that were already going to fall out (in some cases, weeks or months from now) are released earlier and replaced with new hairs. The visible effect is a temporary increase in shedding, typically lasting 4 to 8 weeks.

For finasteride and dutasteride, a smaller subset of patients experience similar transient shedding as the medication shifts follicle dynamics.

What it looks like

Patients describe finding more hairs on the pillow, in the shower drain, or on the brush. The amount is usually moderate, not dramatic. Hair density does not visibly drop in the mirror, but the loose hair count increases.

What it means

Early shedding is an effect of starting treatment, not a measure of how well that treatment will eventually work. It does not reliably predict the outcome in either direction: many patients who respond well never shed at all, and shedding does not guarantee a strong response. What can be said is that it is usually temporary, that it stops on its own, and that new hairs typically begin to grow in over the following weeks.

For that reason, an early shed is generally not a reason to discontinue treatment. If shedding is heavy, patchy, or still going past month 6, that is worth raising with a physician, since it may point to something other than the medication.

Months 3 to 4: shedding settles, growth begins underneath

By the end of month 3, the shedding phase typically subsides. New hair has begun to grow but is still very short, often only a few millimetres long, and not yet visible at the surface in any meaningful way. Trichoscopy can detect the new growth at this stage, but visual examination of the scalp shows little change.

This is one of the most challenging periods psychologically. The shedding has stopped, but visible improvement has not yet started. Many patients report that this is when they most doubt whether the treatment is working.

The biological reality is that follicles are now actively producing new hair; that hair simply has not yet grown long enough to thicken the apparent density on the scalp.

Months 4 to 6: first visible signs of improvement

By month 4 or 5, the new hair has grown long enough to begin contributing to overall density. Patients often describe the early visible improvements as:

• The scalp is less visible through the hair than it was at month 1
• Existing hair appears slightly thicker
• Fine new hairs are visible at the hairline or in the crown region
• Photographs from above show subtle but real changes from baseline

This is the period when most patients first feel confident that the treatment is working. Side-by-side photos from month 0 and month 6 typically show the change more clearly than day-to-day mirror checks, which is why consistent photographic documentation is recommended throughout treatment.

The magnitude of improvement varies based on the stage of follicle miniaturization when treatment began, the medications used, and individual response.

Months 6 to 12: the bulk of cosmetic gains

The window from month 6 to month 12 is when most of the cosmetic benefit of treatment becomes apparent. During this period:

• Hair density continues to improve, particularly at the crown
• The hairline often stabilises, and any recession may slow or halt
• Existing thin hair becomes thicker
• Bald or sparse regions may partially refill, particularly in earlier stages of loss

By the end of the first year, patients have generally achieved most of the visible improvement they will see from treatment. Outcomes during the second year are more about preserving and consolidating gains than producing additional dramatic improvement.

This pattern is consistent across most studies of minoxidil and finasteride monotherapy, as well as combination therapy.

After year one: maintenance

From the start of year two onward, the treatment shifts from active improvement to maintenance. The clinical reality is:

• Hair loss in androgenetic alopecia is chronic, and the underlying mechanism does not disappear with treatment
• Continued medication maintains the progress already achieved
• Discontinuation typically leads to a return of the original loss within 6-12 months

This is covered in more detail on our what happens if you stop treatment page.

Some patients do see additional gains during year two, particularly with combination therapy and adjunctive interventions like microneedling, but the magnitude is typically smaller than during year one.

Differences between medications

The general timeline above applies to most pattern hair loss treatments, but each medication has nuances:

Minoxidil

• Shedding phase common in months 2-3
• First visible improvements typically months 4-6
• Plateau of effect by month 12 in most users
• Stops working if discontinued; gains lost over 3-6 months

Finasteride

• Shedding phase less common but possible
• First visible improvements typically months 3-6
• Continued improvement possible through month 12 and beyond
• Stops working if discontinued; gains lost over 6-12 months

Dutasteride

• Similar timeline to finasteride
• May produce additional improvement when used after finasteride; comparison detailed on our finasteride vs dutasteride page
• Long half-life means slower onset and slower offset of effect

Combination therapy

• Typically faster initial response than monotherapy
• More substantial overall improvement in clinical trials
• Same year-one timeline pattern, with greater magnitude

What can affect the timeline

Several factors influence individual timelines:

• Stage of hair loss when treatment begins: earlier stages tend to show faster and more dramatic improvement
• Consistency of use: daily adherence is essential; missed doses reduce effectiveness
• Concurrent factors: nutritional status, thyroid function, iron levels, and chronic illness can affect hair growth
• Individual response: genetic and physiological variation produces real differences in how quickly and how much patients respond

A physician can help interpret response and adjust treatment if early progress is slower than expected.

How to track progress

Day-to-day mirror checks are unreliable for assessing pattern hair loss treatment because the changes are too gradual to perceive in real time. The recommended approach is:

• Standardized monthly photos in consistent lighting, from front, top, and crown angles
• Avoid changing hairstyle or product use between photos
• Compare months 0, 3, 6, 9, and 12 side by side rather than month-over-month
• Track any specific concerns (specific patches, hairline reference points) as anchors

Many patients are surprised by how much progress is visible in photographic comparisons that they did not perceive day to day.

Considering medical assessment

Treatment for pattern hair loss requires a structured plan and ongoing follow-up to interpret response. A physician can assess baseline status, set realistic expectations, and adjust treatment based on outcomes over time.

Curekey is a HIPAA-compliant telehealth platform that connects patients with licensed U.S. physicians for assessment, prescription, and follow-up. Treatment plans typically include built-in follow-up at 6 and 12 months to evaluate response. Prescriptions are issued only when medically appropriate, and medications are fulfilled by licensed pharmacies. The full process is described on the how it works page.

Related reading

• Hair loss overview
• Androgenetic alopecia explained
• DHT and hair loss
• Follicle miniaturization
• Minoxidil vs finasteride
• What happens if you stop treatment
• Stages of pattern hair loss
• How Curekey works

Key references

• Olsen EA. J Am Acad Dermatol, 1999. Female pattern hair loss.
• Sinclair R. BMJ, 1998. Male pattern androgenetic alopecia.
• Hagenaars SP et al. PLOS Genetics, 2017. Genetic prediction of male pattern baldness.